Seattle Genetics (SGEN) shares are up 9% in pre-market hours today following the news that Merck will make a $1 billion equity investment …
And we have a winner. After a long and arduous development process, only a few biotech names will emerge having attained the ultimate …
Seattle Genetics (SGEN) has announced that its drug TUKYSA (tucatinib) has been approved by the FDA for metastatic HER2 positive breast cancer patients, …
A recession could be headed your way, warns Goldman Sachs — and that’s okay. In a recent report, Goldman private wealth management chief …
Shares of Seattle Genetics, Inc. (NASDAQ:SGEN) are tumbling nearly 10% in Monday’s trading session, after the drug maker announced topline data from its ECHELON-1 Phase …
This morning, Immunomedics, Inc. (NASDAQ:IMMU) and Seattle Genetics, Inc.
Cantor analyst Mara Goldstein sheds light on Seattle Genetics, Inc. (NASDAQ:SGEN) after the bad news broke of a FDA partial hold placed on clinical …
Seattle Genetics, Inc. (NASDAQ:SGEN) reported financial results for the fourth quarter and year ended December 31, 2015.
Seattle Genetics, Inc. (NASDAQ:SGEN) reported financial results for the second quarter and six months ended June 30, 2015.
Seattle Genetics, Inc. (NASDAQ:SGEN) announced the initiation of a phase 2 clinical trial evaluating ADCETRIS (brentuximab vedotin) in systemic lupus erythematosus (SLE, or lupus).